Clinical Trials Logo

Dyskinesia, Drug-Induced clinical trials

View clinical trials related to Dyskinesia, Drug-Induced.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05297201 Recruiting - Parkinson Disease Clinical Trials

Efficacy, Safety and Pharmacokinetic Study of CPL500036 in Patients With Levodopa Induced Dyskinesia

Start date: November 2, 2021
Phase: Phase 2
Study type: Interventional

The aim of the study is to determine potential anti-dyskinetic properties of CPL500036 (PDE10A inhibitor) in Parkinson disease patients suffering from levodopa Induced dyskinesia. The study is to determine the efficacy and dose response of two CPL500036 doses, compared with placebo.

NCT ID: NCT05116813 Recruiting - Parkinson Disease Clinical Trials

Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based Therapy

Start date: October 25, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

This open-label study is designed to assess the long-term safety and tolerability of dipraglurant in PD patients for up to 52 weeks (at doses of 150-300 mg per day) for patients that have completed an Addex sponsored double-blind clinical trial of dipraglurant.

NCT ID: NCT04857359 Recruiting - Parkinson Disease Clinical Trials

Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy

Start date: August 6, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

This study is designed to evaluate the safety and efficacy of dipraglurant in PD patients with dyskinesia (randomized 1:1 to receive active or placebo) for 12 weeks (1 week at 150 mg per day and 11 weeks at 300 mg per day). The primary efficacy assessment will be based on the Unified Dyskinesia Rating Scale (UDysRS). Patients who complete the 12-week blinded treatment period may have the option to roll into an open-label safety extension study for an additional 12-month treatment period.

NCT ID: NCT04064294 Recruiting - Parkinson Disease Clinical Trials

Preventing Levodopa Induced Dyskinesia in Parkinson's Disease With HMG-CoA Reductase Inhibitors

STAT-PD
Start date: June 1, 2019
Phase:
Study type: Observational

In this study, the investigators will examine the association of statin use and dyskinesia in a convenience sample Parkinson's disease patients in the Veterans Administration Health Care System.

NCT ID: NCT00837707 Recruiting - Clinical trials for Dyskinesia, Drug-Induced

Aripiprazole for Neuroleptic-Induced Tardive Dyskinesia

Start date: June 2008
Phase: Phase 4
Study type: Interventional

The aim of the present study was to investigate the efficacy of aripiprazole in management of pre-existing neuroleptic-induced tardive dyskinesia